Home 2017-05-08T02:45:42+00:00

Novel cancer therapies targeting key cancer pathways

READ MORE
Prescient Therapeutics PTX

We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.

prescient therapeutics

OUR COMPANY

Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Read more

prescient therapeutics

OUR SCIENCE

Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.

Read more

prescient therapeutics

LATEST NEWS

1/05/2017AML Clinical Trial Conference call with Jeff Lancet and Said SebtiLISTEN
READ
1/05/2017FDA Grants Orphan Drug Designation for PTX-200 in Acute Myeloid LeukemiaPDF
20/04/2017 AML Update - Conference call with Principal InvestigatorPDF
06/04/2017 Successful Completion of Phase 1b Breast Cancer TrialPDF
04/04/2017 Trading HaltPDF